about
Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myelomaSurvival regulation of leukemia stem cellsDual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myelomaA novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistanceLoss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia.A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myelomaFunctional ramifications for the loss of P-selectin expression on hematopoietic and leukemic stem cells.Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myelomaCSNK1α1 mediates malignant plasma cell survival.A tumor suppressor function of the Msr1 gene in leukemia stem cells of chronic myeloid leukemia.Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells.The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells.Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma.Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myelomaA novel rapid-onset high-penetrance plasmacytoma mouse model driven by deregulation of cMYC cooperating with KRAS12V in BALB/c mice.Preclinical pharmacodynamic evaluation of drug candidate SKLB-178 in the treatment of non-small cell lung cancer.Discovery of New SIRT2 Inhibitors by Utilizing a Consensus Docking/Scoring Strategy and Structure-Activity Relationship Analysis.Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma.Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
P50
Q24598483-77682B0E-7DDC-4660-B6CB-87525CD421F0Q28271278-E0AAF2F7-56F4-46F7-AAA6-92A40AD436ACQ28271286-42825D32-A33E-4176-AE43-74B5AD2298C4Q28395203-2B94EE52-B070-49E5-AF64-3861A509B5BFQ33921399-55C79419-D203-419F-9D5E-2859929365C3Q33944281-BC66E608-4B74-4FAB-BBEF-B6ADAB8CADFEQ34062313-83E33D5E-775A-4550-BCB0-DFC336837CD8Q34194704-A52D5E32-1844-4C10-A6B2-D7D3BB55BB95Q34369823-85254F25-D882-4AB3-B196-5925F3875372Q34774056-989C1256-3DE3-4213-921E-10456BF809F2Q35112252-0D5F24C0-6B32-40F8-AED5-D7130B5C7418Q35119075-7022FC62-937F-4609-B4A5-01A3BB267416Q35900937-318A101A-ECDD-4D6D-9F18-63F8733D3844Q36129530-7C5B49DD-89FA-46EB-B9D6-60F0AC690D61Q36172671-6559BBFF-298A-46A2-8CCA-012B779D7BADQ36206430-62F27CFE-05FB-42A0-96D6-869B0EBF1597Q37431980-AB2EB84D-C57A-4D61-9461-00F9A8866633Q37706510-2427D350-A0C3-423E-A1FD-9D2F7067654EQ38712017-1AEFD2E5-B7DE-441A-8058-FA67BB3606EAQ38961496-28014D71-314F-415E-BEAF-3AFD721716D8Q44851706-A284CB1E-90E8-4664-9006-7A9550996D31
P50
description
researcher ORCID ID = 0000-0002-3973-2140
@en
wetenschapper
@nl
name
Yiguo Hu
@ast
Yiguo Hu
@en
Yiguo Hu
@nl
type
label
Yiguo Hu
@ast
Yiguo Hu
@en
Yiguo Hu
@nl
prefLabel
Yiguo Hu
@ast
Yiguo Hu
@en
Yiguo Hu
@nl
P106
P31
P496
0000-0002-3973-2140